Minerva Neurosciences Jumps 339% On $200M Financing Agreement

October 21, 2025 — 12:57 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Minerva Neurosciences, Inc. (NERV) surged 339.33% to trade at $11.73, up $9.06, after announcing a $200 million financing deal with institutional investors to advance its schizophrenia drug candidate, roluperidone.

The agreement provides $80 million upfront, another $80 million through Tranche A warrants, and $40 million via milestone-based Tranche B warrants. The funding will help support a confirmatory Phase 3 trial, NDA resubmission, and potential U.S. commercial launch.

On Tuesday, NERV opened at $3.02, reached a high of $12.15, and a low of $2.97, compared to a previous close of $2.67 on the Nasdaq Capital Market. Trading volume topped 70 million shares, significantly above its average of 0.8 million. The stock's 52-week range is $1.03 - $12.15.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Minerva Neurosciences Jumps 339% On $200M Financing Agreement

Tags

Latest Articles